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Objective Hypertensive disorders in pregnancy signal an increased
risk of cardiovascular disease for women. However, future
hypertension risk among pregnant women with moderately
elevated blood pressure (BP) is unknown. We examined
associations among moderately elevated BP or hypertensive
disorders during pregnancy and later prehypertension or
hypertension.
Design Longitudinal cohort study.
Setting Five communities in Michigan, USA.
Sample Data are from pregnant women enrolled in the Pregnancy
Outcomes and Community Health Study. We included 667
women with gestational BP measurements who participated in the
POUCHmoms Study follow-up 7–15 years later.
Methods Moderately elevated BP was defined as two measures of
systolic BP ≥ 120 mmHg or diastolic BP ≥80 mmHg among
women without a hypertensive disorder. Weighted multinomial
logistic regression models estimated odds of prehypertension or
hypertension at follow-up, adjusted for maternal confounders and
time to follow-up.
Main outcome measures Prehypertension or hypertension.
Results Women meeting the moderately elevated BP criteria
(64%) had significantly higher odds of hypertension at follow-up
(adjusted odds ratio 2.6; 95% confidence interval 1.2–5.5). These
increased odds were observed for moderately elevated BP first
identified before or after 20 weeks of gestation, and for elevated
systolic BP alone or combined with elevated diastolic BP.
Conclusions Moderately elevated BP in pregnancy may be a risk
factor for future hypertension. Pregnancy offers an opportunity to
identify women at risk for hypertension who may not have been
identified otherwise.
Keywords Blood pressure, diastolic pressure, hypertension,
pregnancy, prehypertension, systolic pressure.
Tweetable abstract Moderately elevated blood pressure in
pregnancy may be associated with hypertension later in life.
Linked article This article is commented on by HA Boyd, p. 1614
in this issue. To view this mini commentary visit https://doi.org/
10.1111/1471-0528.14707.
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Introduction
Hypertension (HTN), defined as systolic blood pressure
(SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP)
≥ 90 mmHg, is prevalent among 30% of the adult popula-
tion in the USA and England.1,2 HTN is an established risk
factor for subsequent cardiovascular and renal diseases, and
contributes to more cardiovascular (CVD) events in
women than men.3,4 In addition, prehypertension
(preHTN), defined as SBP of 120–139 mmHg and/or DBP
of 80–89 mmHg, is a recognised risk factor for subsequent
CVD.5–9
Normal pregnancy may be a ‘stress test’ for the mother,
bringing with it numerous physiological changes including
increased cardiac output and blood volume with blood
pressure (BP) changes.10 BP remains at approximately the
same level from pre-pregnancy through to the end of the
first trimester, after which it drops.10–12 It increases again
in the latter part of the second trimester and continues to
increase until the birth. Pregnancy-onset hypertension and*GL Dunietz and KL Strutz contributed equally as first author.
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pre-eclampsia are characterised by BP ≥ 140 mmHg sys-
tolic or 90 mmHg diastolic on two occasions after
20 weeks of gestation, with pre-eclampsia also including
presence of proteinuria, or severe features.13,14 Chronic
hypertension is diagnosed as BP ≥ 140 mmHg systolic or
90 mmHg diastolic before pregnancy or before 20 weeks of
gestation with failure to resolve postpartum.14 Prevalence
of these disorders, collectively known as hypertensive disor-
ders of pregnancy (HDP), ranges from 5% to 10%.15 How-
ever, there are no existing criteria for preHTN during
pregnancy and the long-term maternal risks associated with
moderate BP elevation are unknown.
In addition to their association with adverse birth out-
comes, HDP also carry long-term risks for HTN and
CVD.16,17 HDP have been consistently associated with
increased risk of future HTN and CVD-related mortal-
ity.18–20 It is not known whether the risk of later-life HTN
is also increased by moderately elevated BP that does not
meet the diagnostic criteria for a hypertensive disorder.
Therefore, our objective was to investigate the risk of later
preHTN and HTN among women with moderately elevated
BP in pregnancy in addition to those diagnosed with HDP.
Further, we examined whether type (i.e. elevated systolic,
diastolic or both) and timing of moderately elevated BP
were differentially associated with later HTN status.
Methods
Study design and analytic sample
We used data from the subcohort of the Pregnancy Out-
comes and Community Health (POUCH) Study.21 A
flowchart of study participants for the current analyses is
shown in Figure 1. Designed to examine pathways leading
to preterm delivery, the initial POUCH Study enrolled
3019 pregnant women from 1998 to 2004 receiving prena-
tal care from 52 clinics in five Michigan communities.
Inclusion criteria were maternal age of at least 15 years,
singleton pregnancies with no known congenital anomalies,
a prenatal maternal serum a-fetoprotein (a-FP) measure
between 15 and 22 weeks of gestation, no diabetes mellitus,
and competency in English. A subcohort of 1371 partici-
pants was created to collect more detailed information and
biological samples. This subcohort included all those deliv-
ering preterm (<37 weeks of gestation) or with elevated
maternal serum a-FP (>2 multiples of the median), and a
random sample of those delivering at term with normal
maternal serum a-FP in which African-American partici-
pants were oversampled. In all analyses sampling weights
are used to account for the cohort and subcohort sampling
strategy. Detailed investigations of biological samples col-
lected at mid-pregnancy and delivery and medical record
abstractions were conducted for the subcohort only, and
these women were the focus of follow-up studies.
POUCHmoms, the most recent follow-up study of the
subcohort, was designed to examine early evidence of CVD
7–15 years after the POUCH Study pregnancy; we hypothe-
sised that pregnancy complications reveal underlying pre-
dispositions to CVD. The POUCHmoms follow-up
included an in-person interview along with measures of
blood pressure, heart rate variability, anthropometrics, car-
otid ultrasound scans and collection of fasting blood sam-
ples for atherogenic biomarkers. A total of 678 participants
Figure 1. Flow chart of participants in the Pregnancy Outcomes and Community Health (POUCH) Study followed in the POUCHmoms Study, 2011–14.
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from the original subcohort completed this protocol from
2011 to 2014. Our analytical sample excluded 11 POUCH-
moms Study participants who were missing BP measure-
ments during pregnancy. Study procedures were
undertaken with the understanding and appropriate
informed consent of each participant.
Measures
Hypertensive status in pregnancy
Eight BP measurements during the POUCH Study preg-
nancy, along with the measurement dates, were abstracted
from the medical record and used for this analysis. These
were the two highest SBP recorded before 20 weeks of ges-
tation, the two highest DBP recorded before 20 weeks of
gestation, the two highest SBP recorded at or after 20
weeks of gestation and the two highest DBP recorded at or
after 20 weeks of gestation.
We categorised a participant as having moderately ele-
vated BP if at least two of her highest SBP readings were
≥ 120 mmHg or at least two of her highest DBP readings
were ≥ 80 mmHg and she did not have HDP (described
below). The moderately elevated BP group was further sub-
divided by whether the elevation was in SBP only, DBP
only, or both. There were only two participants with ele-
vated DBP and normal SBP, so this group was too small to
analyse separately. These women were removed from analy-
ses subdivided by type of elevation. In addition, the moder-
ately elevated BP group was subdivided by gestational week
when moderately elevated BP was first identified, i.e.
<20 weeks, ≥ 20 weeks of gestation. Approximately 26% of
the total moderately elevated BP group had one (but not
two) BP measure of ≥ 140 mmHg SBP or ≥90 mmHg DBP
and did not meet the definition of HDP.
Hypertensive disorder information was derived from med-
ical chart reviews. For these analyses, participants were cate-
gorised with HDP if they were explicitly diagnosed with any
hypertensive disorder (pre-eclampsia/eclampsia, pregnancy-
induced hypertension, chronic hypertension) or met the cri-
teria for any of these disorders on two separate calendar days.
Pre-eclampsia and pregnancy-induced hypertension were
defined as ≥ 140 mmHg SBP or ≥ 90 mmHg DBP on two
occasions after 20 weeks of gestation, with pre-eclampsia
requiring presence of proteinuria. Chronic hypertension was
defined as ≥ 140 mmHg SBP or ≥ 90 mmHg DBO before
pregnancy or before 20 weeks of gestation on two separate
occasions. Women who did not have HDP or chronic hyper-
tension and did not meet our criteria for moderately elevated
BP were classified as normotensive (referent group).
Participants with a history of hypertensive medication
use were classified with chronic hypertension. All models
were rerun with chronic hypertensive participants (n = 26)
removed from the HDP group. The results did not differ,
so the chronic hypertensive participants were retained in
the final sample.
Hypertensive status and BP at follow-up
As recommended in the Joint National Committee (JNC7)
guidelines,5 three consecutive BP measurements were made,
1 minute apart, at the POUCHmoms Study visit. Trained
research assistants, who were registered nurses or ultra-
sonographers with experience in BP measurement, mea-
sured BP seated with the arm extended level to the heart,
using either a Panasonic EW3109W (Panasonic Corp.,
Newark, NJ, USA) or an Omron Hem-907 (Omron Health-
care, Inc., Lake Forest, IL, USA) monitor with a small,
medium or large cuff as appropriate. Both digital monitors
were compared with manual readings and with each other
before data collection to ensure that readings were compa-
rable. We averaged the second and third of these blood
pressure recordings for our measure. We categorised hyper-
tensive status at the POUCHmoms Study follow-up
according to the JNC criteria. Hence, participants with SBP
<120 mmHg and DBP <80 mmHg were classified as nor-
motensive, those with SBP between 120 and 139 mmHg or
with DBP between 80 and 89 mmHg were classified with
preHTN, and those with SBP ≥ 140 mmHg or DBP
≥ 90 mmHg or using antihypertensive medications were
classified with HTN.
Covariates
Potential confounders were variables known to be associ-
ated with HTN during and/or after pregnancy. These
included race/ethnicity (dichotomised as African-American
versus white or other), pre-pregnancy body mass index
(BMI; defined as weight in kilograms divided by the square
of height in metres and modelled as continuous), age (con-
tinuous) and parity (categorised as 0, 1 or 2+) at the time
of the POUCH Study pregnancy, Medicaid insurance cov-
erage at the time of the POUCH Study pregnancy as an
indicator of socio-economic status (dichotomised as yes or
no), and the time between the POUCH Study pregnancy
and follow-up (continuous, in years). Race/ethnicity, pre-
pregnancy BMI and Medicaid status were also tested as
potential effect modifiers. BMI at follow-up (continuous)
was evaluated as a potential intermediary variable or effect
modifier.
Statistical analyses
We used univariate and bivariate descriptive statistics to
examine variable distributions overall and across categories
of hypertensive status during pregnancy and follow-up.
Differences by hypertensive status were assessed with Chi-
square tests; P < 0.05 was considered statistically signifi-
cant. Multinomial logistic regression models produced
crude and adjusted odds ratios (ORs) with 95% confidence
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intervals (95% CIs) for preHTN and HTN at follow-up for
each prenatal BP category, with normotensive as the refer-
ent category at both time-points. Differences among the
prenatal BP categories were tested with contrast statements.
These models were run with and without BMI at follow-
up, and were repeated by type and timing of moderately
elevated BP. Effect modification was tested with interaction
terms; none was significant and therefore they were
excluded from the final models.
All analyses were run with the survey procedures in SAS
v9.3 (SAS Institute Inc., Cary, NC, USA) to incorporate the
original POUCH Study sampling design and weighting.
These weights accounted for the oversampling of participants
delivering preterm, with elevated maternal serum a-FP and
of African-American race. For example, in the POUCH-
moms Study follow-up analyses, each woman remained in
her POUCH Study stratum (e.g. white non-Hispanic, normal
maternal serum a-FP, preterm) for the purpose of calculating
sampling weights, thereby maintaining the appropriate pro-
portionality (from the original population) of each stratum
to the total follow-up sample (denominator of 667 for these
analyses). The weights were not altered to account for loss-
to-follow-up in the POUCHmoms Study. However, a sensi-
tivity analysis was conducted with the unweighted data to
determine whether conclusions would differ between
weighted and unweighted analyses.
Results
Characteristics of the analytical sample are compared with
those of the remaining POUCH Study subcohort partici-
pants in the Supplementary material (Table S1). The
women in the follow-up sample were more highly edu-
cated, less likely to have received Medicaid insurance at
pregnancy, more likely to be of white or other race/ethnic-
ity, and more likely to have come from the Lansing com-
munity. However, pre-pregnancy BMI, preterm delivery,
delivery of a small-for-gestational-age infant, and prenatal
BP categories did not differ between women in the follow-
up study and those not followed.
Maternal and pregnancy characteristics by HTN status at
follow-up are displayed in Table 1. White/other women
were more likely to be classified as normotensive at follow-
up compared with African-American women (60% versus
44%). Mean BMI, both pre-pregnancy and at follow-up,
and mean maternal age at both enrolment and follow-up
displayed positive linear associations with HTN status at
follow-up, although age at enrolment was only borderline
Table 1. Maternal characteristics during pregnancy and 7–15 years later by hypertensive status at follow-up
Characteristic
Total n = 667
Normotensive
at follow-up
n = 366 (56%)
Prehypertensive
at follow-up
n = 162 (24%)
Hypertensive
at follow-up
n = 139 (19%)
P value
Race/ethnicity, n (%)
White or other 256 (60) 98 (24) 70 (16) <0.01
African-American 110 (44) 64 (27) 69 (29)
Parity at POUCH pregnancy, n (%)
0 168 (59) 71 (25) 52 (16) 0.11
1 124 (60) 49 (22) 44 (18)
2+ 74 (46) 42 (27) 43 (26)
BMI (kg/m2), mean (range)
Pre-pregnancy BMI 25.4 (16.2–50.4) 27.6 (16.3–52.1) 31.8 (17.3–60.4) <0.01
BMI at follow-up 28.6 (17.0–61.0) 32.8 (20.0–65.0) 37.3 (19.0–64.0) <0.01
Age (years), mean (range)
At POUCH enrolment 26.2 (15.5–39.9) 26.5 (15.8–47.3) 27.9 (16.3–39.6) 0.05
At follow-up 37.4 (25.7–51.3) 38.0 (26.1–58.4) 39.3 (26.7–52.3) 0.02
Medicaid status in pregnancy, n (%)
Yes 172 (51) 89 (26) 80 (23) 0.07
No 194 (61) 73 (23) 59 (16)
Interval between birth and follow-up
(years), mean (range)
10.9 (7.7–14.7) 11.2 (7.7–15.1) 11.1 (8.0–14.7) 0.12
Blood pressure in pregnancy
Normotensive 122 (64) 49 (28) 19 (9) <0.01
Moderately elevated BP 223 (59) 89 (22) 87 (13)
Hypertensive disorder 21 (24) 24 (32) 33 (43)
%, weighted percentage.
All percentages and means are based on weighted data.
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significant. Parity and Medicaid enrolment in pregnancy
did not vary across HTN groups. Similarly, for all study
groups the observed mean number of years from the
POUCH Study birth to re-enrolment into the POUCH-
moms Study, approximately 11 years, was not associated
with HTN. Finally, HTN status at follow-up differed by
HTN status in pregnancy: of the normotensive in preg-
nancy group, 64% were normotensive at follow-up, 28%
had preHTN and only 9% met HTN criteria; among the
group with moderately elevated BP in pregnancy, 59% were
normotensive at follow-up, whereas 22% and 13% had
preHTN and HTN, respectively; in the HDP group, 24%
were normotensive later in life, 32% had preHTN and 43%
had HTN. The maternal and pregnancy characteristics by
HTN status in pregnancy can be seen in the Supplementary
material (Table S2).
Multinomial logistic regression results are shown in
Table 2. Women with moderately elevated BP in pregnancy
Table 2. The relation between blood pressure in pregnancy and hypertensive status at 7–15 years follow-up
Prehypertensive at follow-up (n = 162) Hypertensive at follow-up (n = 139)
Model 1:
Unadjusted
OR (95% CI)
Model 2:
Adjusted
OR*,**
(95% CI)
Model 3:
Model 2 + BMI
Adjusted OR*,***
(95% CI)
Model 1:
Unadjusted OR
(95% CI)
Model 2:
Adjusted
OR*,**
(95% CI)
Model 3:
Model 2 + BMI
Adjusted OR*,***
(95% CI)
Section A: Blood pressure in pregnancy
Normotensive
(n = 190)
1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent]
Moderately
elevated BP
(n = 399)
0.8 (0.5, 1.4) 0.8 (0.5, 1.4) 0.7 (0.4, 1.3) 2.4 (1.3, 4.6) 2.6 (1.2, 5.5) 2.3 (1.0, 5.1)
Hypertensive
disorder (n = 78)
3.0 (1.3, 7.1) 3.0 (1.2, 7.7) 2.5 (0.9, 6.6) 13.2 (5.3, 32.8) 16.3 (5.5, 49.0) 13.7 (4.4, 42.9)
Section B: Blood pressure in pregnancy by type of elevation****
Normotensive
(n = 190)
1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent]
Moderately
elevated, systolic
only (n = 156)
0.8 (0.4, 1.5) 0.8 (0.4, 1.5) 0.7 (0.4, 1.3) 2.1 (1.0, 4.6) 2.5 (1.1, 6.0) 2.3 (0.9, 5.7)
Moderately
elevated, both
systolic and
diastolic (n = 241)
0.9 (0.5, 1.5) 0.8 (0.5, 1.5) 0.7 (0.4, 1.4) 2.7 (1.3, 5.3) 2.7 (1.2, 6.0) 2.4 (1.0, 5.5)
Hypertensive
disorder (n = 78)
3.0 (1.3, 7.1) 3.0 (1.2, 7.6) 2.5 (0.9, 6.6) 13.2 (5.3, 32.8) 16.4 (5.5, 49.3) 13.7 (4.4, 43.2)
Section C: Blood pressure in pregnancy by timing of elevation
Normotensive
(n = 190)
1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent] 1 [Referent]
Moderately
elevated, early
(<20 weeks of
gestation; n = 97)
0.9 (0.4, 1.9) 0.8 (0.3, 1.9) 0.7 (0.3, 1.7) 4.0 (1.8, 9.0) 3.4 (1.3, 9.0) 3.2 (1.2, 8.6)
Moderately
elevated,
late (≥ 20 weeks
of gestation;
n = 302)
0.8 (0.5, 1.4) 0.8 (0.5, 1.4) 0.7 (0.4, 1.3) 2.0 (1.0, 4.0) 2.4 (1.1, 5.3) 2.1 (0.9, 4.9)
Hypertensive
disorder (n = 78)
3.0 (1.3, 7.1) 3.0 (1.1, 7.7) 2.5 (0.9, 6.7) 13.2 (5.3, 32.8) 16.9 (5.6, 50.9) 14.2 (4.5, 44.8)
*Coefficients are based on weighted data.
**Adjusted for race/ethnicity; pre-pregnancy BMI; age, parity, and Medicaid at pregnancy; and interval between birth and follow-up.
***Adjusted for all covariates listed above plus BMI at follow-up.
****n = 665 for these models, which exclude those with moderately elevated diastolic BP only (n = 2).
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had significantly increased odds of HTN at follow-up in
the crude model (Section A, Model 1: OR 2.4, 95% CI 1.3–
4.6) and the model adjusted for pregnancy confounders
(Model 2: OR 2.6, 95% CI 1.2–5.5) (Table 2). Adding BMI
at follow-up to the adjusted model attenuated the OR
slightly (Model 3: OR 2.3, 95% CI 1.0–5.1). Moderately
elevated BP in pregnancy was not associated with follow-
up preHTN in any models. As expected, HDP were posi-
tively associated with later preHTN and HTN; again BMI
at follow-up modestly attenuated the effect estimates
(Model 3: preHTN OR 2.5, 95% CI 0.9–6.6; HTN OR 13.7,
95% CI 4.4–42.9).
Results with moderately elevated BP in pregnancy divided
by type and timing are shown in Table 2, Sections B and C,
respectively. Moderately elevated SBP in pregnancy, alone
and in combination with elevated DBP, significantly
increased the odds of HTN at follow-up in most models
(Table 2, Section B). Early moderately elevated BP
(<20 weeks of gestation) significantly increased the odds of
HTN three- to four-fold at follow-up in all models (Table 2,
Section C). Late moderately elevated BP (≥ 20 weeks of ges-
tation) was not statistically significantly associated with HTN
at follow-up after controlling for BMI at follow-up, although
it led to approximately double the odds of HTN in all mod-
els. The odds ratios for HTN at follow-up for early moder-
ately elevated BP were significantly higher than those for
later moderately elevated BP (P < 0.05). The sensitivity anal-
ysis repeating all models with unweighted data produced
similar results (see Table S3).
Discussion
Main findings
This prospective study followed pregnant women to exam-
ine their health status 7–15 years later. We found that
moderately elevated BP in pregnancy is significantly associ-
ated with approximately twice the odds of future HTN.
This is true whether SBP is elevated alone or in conjunc-
tion with elevated DBP. The observed association between
moderately elevated BP and future HTN is larger when BP
is elevated before 20 weeks of gestation, the gestational cut-
off used for distinguishing chronic, pre-existing HTN from
pregnancy-induced HTN,13,14 but is also seen when BP is
elevated later.
Strengths and limitations
One limitation of this work is the differences in some char-
acteristics between the POUCH Study subcohort partici-
pants followed versus those not followed that could
potentially lead to selection bias. However, it was reassur-
ing that these differences did not occur based on pregnancy
outcome (term versus preterm, small-for-gestational-age)
or on BP. In addition, the potential follow-up biases
present (e.g. maternal education, Medicaid) applied equally
to each of the sampling strata; therefore, our approach to
using the original POUCH Study strata for calculating
sampling weights did not appear to introduce additional
follow-up bias. Instead, our weighting by race/ethnicity-
specific strata helped to account for some of the differential
in follow-up by race/ethnicity.
Additional limitations include that we were able to assess
moderately elevated BP only in the POUCH Study pregnan-
cies, without knowledge of whether it occurred in previous
or later pregnancies as well. It is plausible that recurring
moderately elevated BP is more indicative of later HTN risk;
research in other cohorts will be necessary to test this
hypothesis. We did not have measurements of pre-pregnancy
BP to establish whether any participants had preHTN before
pregnancy. However, it is worth noting that many women of
reproductive age do not know this information themselves
before entering prenatal care. Furthermore, our BP measure-
ments in pregnancy were part of the participants’ clinical
care rather than standardised by a study protocol, and not all
BP measurements were abstracted for the POUCH Study.
Our follow-up BP categories were based on BP measured at
one study visit; repeated BP measures over time might
remove some intra-individual variability and provide more
precise confidence limits.
Finally, given the age range of the participants at follow-
up, our study was limited to examining early development of
HTN and could not assess CVD-related events. However, the
associations seen here between moderately elevated BP dur-
ing pregnancy and HTN in young and middle-aged adults
confirm the potential for identifying at-risk women earlier in
their lives. Our follow-up period of 7–15 years is comparable
to those of studies showing progression of preHTN to CVD
outcomes in the general population.6–9
Despite these limitations, our study has several strengths.
First, to our knowledge, it is the first to apply the preHTN
criteria to a pregnant population to assess odds of later
HTN. Second, the population represents a socio-economic-
ally diverse community-based sample followed longitudi-
nally. Third, both the POUCH Study and its
POUCHmoms follow-up contain rich measures, including
objective BP measurements that allow for deeper investiga-
tion of the mechanisms underlying the phenomena
reported here.
Interpretation
Although our results confirm previous reports outside
pregnancy that elevated BP is associated with later life
HTN,22–31 our study is novel, as it applies the preHTN cri-
teria used in the general population to pregnancy. Our
findings extend studies of preHTN in the general popula-
tion that demonstrate the importance of elevated SBP in
progressing to HTN.23,24 It had previously been assumed
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that only moderate to severe HDP presented a concern for
maternal and infant health.29 However, emerging evidence
suggests that elevated BP among pregnant women without
HDP is associated with increased risk of poor offspring
health outcomes including fetal growth restriction and pre-
term delivery.32–35 Our study extends these findings to an
adverse maternal health outcome in later life.
Our data showing a stronger association between later
HTN and moderately elevated BP before 20 weeks of gesta-
tion points to the first half of pregnancy as particularly
revealing because it detects women with previously undiag-
nosed preHTN, and/or women who do not show the typi-
cal lowering of BP in response to pregnancy-related
physiological changes arising during these gestational
weeks. Women in our sample with moderately elevated BP
only after 20 weeks of gestation also had higher odds of
HTN at follow-up, although the effect size was smaller.
Women with later moderately elevated BP onset offer fur-
ther evidence that pregnancy may unmask an increased risk
of HTN in affected women who enter pregnancy with nor-
motensive BP. Future research will be needed to shed
greater light on these critical windows.
Given the physiological changes of pregnancy, it is not
surprising that moderately elevated BP is highly prevalent
in pregnancy when moderately elevated BP is defined by
prehypertensive cut-offs used for nonpregnant populations.
Our finding that 64% of women had moderately elevated
BP in pregnancy suggests that our definition, parallel to the
JNC7 definition of preHTN,5 has high sensitivity but low
specificity for predicting later HTN. It is surprising that
there is no association between moderately elevated BP in
pregnancy and later preHTN, given that preHTN is often
on the pathway to hypertension. This null finding may
reflect that moderately elevated BP is not a constant state,
and repeated measures are needed to better identify women
who truly belong in this category.
Conclusion
In conclusion, we identified a significant association
between moderately elevated BP in pregnancy and later
HTN. This approach parallels that of the increasing recog-
nition that pregnancy factors such as gestational weight
gain have immediate consequences for perinatal outcomes
as well as long-term impacts on maternal metabolic and
cardiovascular health.36 In future work, we will focus on
further improving the prediction of later life HTN by con-
sidering gestational BP measurements alongside other
biomarkers measured in pregnancy. Given that pregnancy
represents a time of frequent contact between women and
the healthcare system, our findings for moderately elevated
BP suggest that prenatal care may be an effective time to
identify women at risk of later HTN beyond identifying
women with hypertensive disorders of pregnancy. Closer
monitoring of women with gestational moderately elevated
BP coupled with timely intervention may help to curtail
the incidence of CVD among at-risk women.
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